Skip to main content
Back to News
OpenAI unveiled GPT‑Rosalind, a biology‑tuned LLM designed for evidence synthesis, hypothesis genera...
Product
1 min read
US

OpenAI unveiled GPT‑Rosalind, a biology‑tuned LLM designed for evidence synthesis, hypothesis genera...

The AMW Read

This updates the OpenAI case study (01.§4) by demonstrating a significant vertical expansion into high-value biology/drug discovery workflows, validated by top-tier industry adopters like Amgen and Moderna.
NoveltySignificance
Healthcare & Bio · Player MapFoundation Models · Case Studies

OpenAI unveiled GPT‑Rosalind, a biology‑tuned LLM designed for evidence synthesis, hypothesis generation and experimental planning in drug discovery and translational medicine. The model is available via a research preview in ChatGPT, Codex and API, with a free Life Sciences plugin linking to 50+ scientific tools. Early adopters include Amgen, Moderna and Thermo Fisher, signaling a shift toward AI‑driven acceleration of early‑stage research. 🚀

#AI #LifeSciences #DrugDiscovery #Biotech #OpenAI

How This Connects

Based on Healthcare & Bio · Player Map

  1. 9h agoIsomorphic Labs explores funding at a valuation of at least $40 billionIsomorphic Labs
  2. 1w agoApheris and Ginkgo launch antibody AI consortium with four pharma companiesApheris
  3. 1w agoEnveda raises $311 million to advance AI-discovered natural-molecule drugsEnveda
  4. 3w agoLevel Five, a game developer, has issued a public apology after facing criticism for what it called...Level Five
  5. 5mo agoOpenAI unveiled GPT‑Rosalind, a biology‑tuned LLM designed for evidence synthesis, hypothesis genera... · THIS ARTICLE

Related News

More news from Codex

Stay updated with the latest news and announcements from Codex.

View all Codex news

Discover AI Startups

Explore 5,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard